Josquin Moraly, Julien Rossignol, Claire Rouzaud, Thomas Gabas, Hassiba Bouktit, Ludovic Lhermitte, Danielle Canioni, Sylvie Fraitag, Julie Bruneau, Stéphane Barete, Felipe Suarez, Thomas Ballul, Cécile Meni, Laura Polivka, Louis Terriou, David Launay, Laurence Bouillet, Caroline Gaudy-Marqueste, Marie Gousseff, Edwige Le Mouel, Antoine Neel, Dana Ranta, Roland Jaussaud, Philippe Guilpain, Laurent Frenzel, Julie Agopian, Patrice Dubreuil, Céline Greco, Sophie Dimicoli-Salazar, Mael Heiblig, Clément Gourguechon, Olivier Tournilhac, Rose-Marie Javier, Florence Castelain, Quentin Cabrera, Marie Pierre Gourin, Ewa Wierzbicka-Hainaut, Jose Miguel Torregrosa-Diaz, Cristina Bulai, Christian Lavigne, Cyrille Hoarau, Michel Arock, Gandhi Damaj, Olivier Lortholary, Olivier Hermine
Systemic mastocytosis (SM) corresponds to a rare and heterogeneous spectrum of diseases characterized by the accumulation of atypical mast cells (MCs). Advanced mastocytosis (Adv-SM) is associated with poor survival; in contrast, patients with non-advanced SM (non-Adv-SM) usually have a normal life expectancy but may experience poor quality of life. Despite recent therapeutic progress including tyrosine kinase inhibitors, new treatment options are needed for refractory and/or intolerant patients with both severely symptomatic and Adv-SM...
April 6, 2024: American Journal of Hematology